1. Repositório Institucional - INCA
  2. Comunicação
  3. Revistas e Informes
  4. Informe INCA
  5. Informe INCA 2022
  6. Informe INCA 417
Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/6276
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorINCA-
dc.date.accessioned2022-04-06T14:17:49Z-
dc.date.available2022-04-06T14:17:49Z-
dc.date.issued2022-03-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/6276-
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.subjectNeoplasias do Colo do Útero/terapiapt_BR
dc.subjectUterine Cervical Neoplasms/therapypt_BR
dc.subjectNeoplasias del Cuello Uterino/terapiapt_BR
dc.subjectAvaliação de Medicamentospt_BR
dc.subjectDrug Evaluationpt_BR
dc.subjectEvaluación de Medicamentospt_BR
dc.subjectCemiplimabept_BR
dc.subjectMelo, Andréia Cristina dept_BR
dc.titleINCA participa de estudo inédito sobre novo fármaco para câncer do colo do úteropt_BR
dc.title.alternativeInforme INCA 417pt_BR
dc.TypeArticlept_BR
Appears in Collections:Informe INCA 417

Files in This Item:
File Description SizeFormat 
Informe-INCA-2022-417-4-INCA-participa-de.pdf219.12 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.